JP7680950B2 - 生存分析によるクラス不均衡セットのダウンサンプリングを組み合わせた疾患リスクを判定するための方法 - Google Patents

生存分析によるクラス不均衡セットのダウンサンプリングを組み合わせた疾患リスクを判定するための方法 Download PDF

Info

Publication number
JP7680950B2
JP7680950B2 JP2021530139A JP2021530139A JP7680950B2 JP 7680950 B2 JP7680950 B2 JP 7680950B2 JP 2021530139 A JP2021530139 A JP 2021530139A JP 2021530139 A JP2021530139 A JP 2021530139A JP 7680950 B2 JP7680950 B2 JP 7680950B2
Authority
JP
Japan
Prior art keywords
class
dataset
data
data class
imbalanced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021530139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509835A5 (enExample
JP2022509835A (ja
Inventor
ハガル，ヨランダ
ダッタ，ガルギ
アレクサンダー，レイ
ヒンテルベルグ，マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Somalogic Inc
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of JP2022509835A publication Critical patent/JP2022509835A/ja
Publication of JP2022509835A5 publication Critical patent/JP2022509835A5/ja
Priority to JP2025003207A priority Critical patent/JP2025061136A/ja
Application granted granted Critical
Publication of JP7680950B2 publication Critical patent/JP7680950B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/021—Measuring pressure in heart or blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/103—Measuring devices for testing the shape, pattern, colour, size or movement of the body or parts thereof, for diagnostic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/117—Identification of persons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4866—Evaluating metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4869—Determining body composition
    • A61B5/4872—Body fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7221—Determining signal validity, reliability or quality
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7235—Details of waveform analysis
    • A61B5/7264—Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
    • A61B5/7271—Specific aspects of physiological measurement analysis
    • A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B23/00—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/50—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Artificial Intelligence (AREA)
  • Physiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Psychiatry (AREA)
  • Signal Processing (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dentistry (AREA)
  • Cardiology (AREA)
  • Mathematical Physics (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Obesity (AREA)
  • Fuzzy Systems (AREA)
  • Evolutionary Computation (AREA)
  • Vascular Medicine (AREA)
  • Mathematical Analysis (AREA)
  • Computational Mathematics (AREA)
  • Algebra (AREA)
  • Mathematical Optimization (AREA)
JP2021530139A 2018-11-29 2019-11-21 生存分析によるクラス不均衡セットのダウンサンプリングを組み合わせた疾患リスクを判定するための方法 Active JP7680950B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025003207A JP2025061136A (ja) 2018-11-29 2025-01-09 生存分析によるクラス不均衡セットのダウンサンプリングを組み合わせた疾患リスクを判定するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862773028P 2018-11-29 2018-11-29
US62/773,028 2018-11-29
US201862783733P 2018-12-21 2018-12-21
US62/783,733 2018-12-21
PCT/US2019/062561 WO2020112478A1 (en) 2018-11-29 2019-11-21 Methods for determining disease risk combining downsampling of class-imbalanced sets with survival analysis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025003207A Division JP2025061136A (ja) 2018-11-29 2025-01-09 生存分析によるクラス不均衡セットのダウンサンプリングを組み合わせた疾患リスクを判定するための方法

Publications (3)

Publication Number Publication Date
JP2022509835A JP2022509835A (ja) 2022-01-24
JP2022509835A5 JP2022509835A5 (enExample) 2022-11-24
JP7680950B2 true JP7680950B2 (ja) 2025-05-21

Family

ID=70852605

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530139A Active JP7680950B2 (ja) 2018-11-29 2019-11-21 生存分析によるクラス不均衡セットのダウンサンプリングを組み合わせた疾患リスクを判定するための方法
JP2025003207A Withdrawn JP2025061136A (ja) 2018-11-29 2025-01-09 生存分析によるクラス不均衡セットのダウンサンプリングを組み合わせた疾患リスクを判定するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025003207A Withdrawn JP2025061136A (ja) 2018-11-29 2025-01-09 生存分析によるクラス不均衡セットのダウンサンプリングを組み合わせた疾患リスクを判定するための方法

Country Status (10)

Country Link
US (1) US20220015714A1 (enExample)
EP (1) EP3886696A4 (enExample)
JP (2) JP7680950B2 (enExample)
KR (1) KR20210099605A (enExample)
CN (1) CN113271849B (enExample)
AU (1) AU2019385818B2 (enExample)
CA (1) CA3120716A1 (enExample)
IL (1) IL283467A (enExample)
SG (1) SG11202105063QA (enExample)
WO (1) WO2020112478A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11996201B2 (en) * 2021-03-04 2024-05-28 Abbott Laboratories Technology to automatically identify the most relevant health failure risk factors
JP7322918B2 (ja) * 2021-03-29 2023-08-08 横河電機株式会社 プログラム、情報処理装置、及び学習モデルの生成方法
KR102393367B1 (ko) 2021-11-15 2022-05-03 오브젠 주식회사 생존 분석 시스템 및 그 제어방법
KR102424884B1 (ko) 2021-11-18 2022-07-27 오브젠 주식회사 생존 데이터 정제 서버와 생존 데이터 분석 서버를 포함하는 시스템 및 그 제어방법
CN114548327A (zh) * 2022-04-27 2022-05-27 湖南工商大学 基于平衡子集的软件缺陷预测方法、系统、设备及介质
CN115114270B (zh) * 2022-06-14 2024-08-02 马上消费金融股份有限公司 数据降采样方法及装置、电子设备、计算机可读存储介质
KR102688743B1 (ko) * 2023-08-16 2024-07-26 렉스이노베이션 주식회사 분산 배터리의 soh에 기초하여 이상을 탐지하는 방법
US20250069754A1 (en) * 2023-08-22 2025-02-27 Elythea, Inc. Predicting risk of pregnancy-related complications using machine learning
CN121015165A (zh) * 2025-06-30 2025-11-28 延边大学 基于多模态特征融合的睡眠呼吸暂停识别方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214397A1 (en) 2016-06-08 2017-12-14 University Of Iowa Research Foundation Compositions and methods for detecting predisposition to cardiovascular disease
WO2018048960A1 (en) 2016-09-07 2018-03-15 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
WO2018141840A1 (en) 2017-02-02 2018-08-09 B.R.A.H.M.S Gmbh Proadm as marker indicating an adverse event

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7982066B2 (en) * 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
AU2010328019A1 (en) * 2009-12-09 2012-06-28 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
US20120269418A1 (en) * 2011-04-22 2012-10-25 Ge Global Research Analyzing the expression of biomarkers in cells with clusters
CN104573708A (zh) * 2014-12-19 2015-04-29 天津大学 组合降采样极限学习机
WO2017059022A1 (en) * 2015-09-30 2017-04-06 Inform Genomics, Inc. Systems and methods for predicting treatment-regiment-related outcomes
GB201614394D0 (en) * 2016-08-23 2016-10-05 Imp Innovations Ltd Method
AU2018100796A4 (en) * 2018-06-14 2018-07-19 Macau University Of Science And Technology A genetic feature identifying system and a search method for identifying features of genetic information

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214397A1 (en) 2016-06-08 2017-12-14 University Of Iowa Research Foundation Compositions and methods for detecting predisposition to cardiovascular disease
WO2018048960A1 (en) 2016-09-07 2018-03-15 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
WO2018141840A1 (en) 2017-02-02 2018-08-09 B.R.A.H.M.S Gmbh Proadm as marker indicating an adverse event

Also Published As

Publication number Publication date
CN113271849A (zh) 2021-08-17
AU2019385818B2 (en) 2025-04-24
KR20210099605A (ko) 2021-08-12
CA3120716A1 (en) 2020-06-04
WO2020112478A1 (en) 2020-06-04
CN113271849B (zh) 2024-08-30
AU2019385818A1 (en) 2021-07-08
JP2025061136A (ja) 2025-04-10
IL283467A (en) 2021-07-29
US20220015714A1 (en) 2022-01-20
EP3886696A4 (en) 2022-08-24
JP2022509835A (ja) 2022-01-24
EP3886696A1 (en) 2021-10-06
SG11202105063QA (en) 2021-06-29

Similar Documents

Publication Publication Date Title
JP7680950B2 (ja) 生存分析によるクラス不均衡セットのダウンサンプリングを組み合わせた疾患リスクを判定するための方法
Kukar et al. COVID-19 diagnosis by routine blood tests using machine learning
Sweeney et al. A community approach to mortality prediction in sepsis via gene expression analysis
Kurstjens et al. Rapid identification of SARS-CoV-2-infected patients at the emergency department using routine testing
JP7431760B2 (ja) 癌分類子モデル、機械学習システム、および使用方法
Schupp et al. Diagnostic and prognostic role of platelets in patients with sepsis and septic shock
Moallemi et al. Early biomarkers for prediction of severe manifestations of dengue fever: a systematic review and a meta-analysis
Fujisawa et al. Nationwide cloud-based integrated database of idiopathic interstitial pneumonias for multidisciplinary discussion
RU2640568C2 (ru) Способы и системы для оценки риска рака желудочно-кишечного тракта
Zheng et al. Prospective accuracy for longitudinal markers
Shi et al. Machine learning-based in-hospital mortality prediction of HIV/AIDS patients with Talaromyces marneffei infection in Guangxi, China
US20130103321A1 (en) Selection of Preferred Sample Handling and Processing Protocol for Identification of Disease Biomarkers and Sample Quality Assessment
MX2008013978A (es) Metodos y aparatos para identificar el estado de enfermedades utilizando biomarcadores.
JP2012502281A5 (enExample)
CN105229471A (zh) 用于基于生物化学标记分析确定先兆子痫风险的系统和方法
US20220084639A1 (en) Electronic Phenotyping Technique for Diagnosing Chronic Kidney Disease
Aguirre et al. Diagnostic performance of machine learning models using cell population data for the detection of sepsis: a comparative study
Pecanha-Pietrobom et al. The clinical course of hospitalized moderately ill COVID-19 patients is mirrored by routine hematologic tests and influenced by renal transplantation
CN118629517B (zh) 用于新冠病毒易感性的预测标志物以及预测方法、装置
Shu et al. Acute ischemic stroke prediction and predictive factors analysis using hematological indicators in elderly hypertensives post-transient ischemic attack
Matejin et al. Risk stratification and prediction of severity of COVID-19 infection in patients with preexisting cardiovascular disease
Sweeney et al. Mortality prediction in sepsis via gene expression analysis: a community approach
HK40059456A (en) Methods for determining disease risk combining downsampling of class-imbalanced sets with survival analysis
JP2024525499A (ja) 機械学習を使用した全血算に基づく異常検出
Lin et al. Monocyte distribution width enhances the detection of infection in patients after primary percutaneous coronary intervention

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250509

R150 Certificate of patent or registration of utility model

Ref document number: 7680950

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150